Wells Fargo & Company Foghorn Therapeutics Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 9,272 shares of FHTX stock, worth $72,599. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,272
Previous 6,079
52.53%
Holding current value
$72,599
Previous $40,000
32.5%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding FHTX
# of Institutions
73Shares Held
32.8MCall Options Held
6KPut Options Held
1.8K-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$99.2 Million8.71% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$41.5 Million0.93% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.52MShares$19.7 Million0.3% of portfolio
-
Raymond James & Associates St Petersburg, FL2.34MShares$18.3 Million0.01% of portfolio
-
Euclidean Capital LLC New York, NY1.57MShares$12.3 Million1.14% of portfolio
About Foghorn Therapeutics Inc.
- Ticker FHTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,637,400
- Market Cap $326M
- Description
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...